Yamazaki Taiji, Hibi Kenji, Takase Tsunenobu, Tezel Ekmel, Nakayama Hiroshi, Kasai Yasushi, Ito Katsuki, Akiyama Seiji, Nagasaka Tetsuro, Nakao Akimasa
Second Department of Surgery, Japan.
Clin Cancer Res. 2002 Jan;8(1):192-5.
We proved recently that PGP9.5-negative pancreatic cancer patients had significantly better survival rates compared with those who were PGP9.5 positive, and PGP9.5 may be a novel marker for indicating the prognosis of pancreatic cancer patients. In this study, we examined the expression of PGP9.5 in primary colorectal cancers using immunohistochemistry and correlated the result with the clinicopathological features.
Of 74 colorectal cancer specimens examined, 33 cases (46%) showed positive staining with PGP9.5 in most tumor cells, whereas no PGP9.5 expression was detected in adjacent normal epithelium. Subsequently, we correlated PGP9.5 expression in tumors with the clinicopathological features of affected patients and found two significant differences in maximal tumor size and the extent of tumor (P = 0.035 and 0.019, respectively).
This result suggests that PGP9.5 expression is related to tumor progression and may be useful as a marker for invasive colorectal cancer.
我们最近证实,与PGP9.5阳性的胰腺癌患者相比,PGP9.5阴性的胰腺癌患者生存率显著更高,且PGP9.5可能是一种指示胰腺癌患者预后的新标志物。在本研究中,我们采用免疫组织化学方法检测了原发性结直肠癌中PGP9.5的表达,并将结果与临床病理特征相关联。
在检测的74例结直肠癌标本中,33例(46%)在大多数肿瘤细胞中显示PGP9.5阳性染色,而在相邻正常上皮中未检测到PGP9.5表达。随后,我们将肿瘤中PGP9.5的表达与受影响患者的临床病理特征相关联,发现最大肿瘤大小和肿瘤范围存在两个显著差异(P值分别为0.035和0.019)。
该结果表明PGP9.5表达与肿瘤进展相关,可能作为浸润性结直肠癌的标志物。